Jonathan Trent, MD, PhD on Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib @JTrentMDPhD @SylvesterCancer

Jonathan Trent, MD, PhD on Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib @JTrentMDPhD @SylvesterCancer

User Photo
Cancer-News

4 months
7 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.
Up Next Autoplay